Treatment
Cell clinical trials
We’re tracking 5,710 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT07311057Enrolling by invitationPhase 3
Methylene Blue for Skin Cancer Not Removable by Surgery
This trial tests a new methylene blue formula injected into skin cancer tumors that cannot be removed by surgery or treated with radiation. It is for people who have one or more small tumors (each less than 2 cm) and cannot have the usual treatments.
Mashhad, Razavi Khorasan ProvinceAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06985576Enrolling by invitation
Long-term safety follow-up for GF-CART01
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
TaipeiAges Any age - NCT06962449Enrolling by invitation
Study of Tislelizumab as First Treatment for Advanced Lung Cancer
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06782399Enrolling by invitationEarly Phase 1
Drug screening for skin squamous cell cancer lesions
This trial tests a device placed on skin cancer lesions to see which drugs might work best. It is for people with visible squamous cell carcinoma on the skin, including lesions that have come back after radiation.
Boston, MassachusettsAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Birmingham, AlabamaAges 18 years+ - NCT04836390Enrolling by invitationPhase 2
Donor immune cell treatment after transplant for high-risk AML
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Phoenix, ArizonaAges birth–25 years - NCT06801834RecruitingPhase 3
Study of sacituzumab govitecan vs. standard care for advanced small cell lung cancer
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
Anchorage, AlaskaAges 18 years+ - NCT07754890RecruitingPhase 1/Phase 2
Study of two drugs for advanced skin lymphoma
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06725550Recruiting
Acupuncture for pain in sickle cell disease
This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.
Cincinnati, OhioAges 14–80 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT07645469RecruitingPhase 1
WT1 T Cell Therapy With Azacitidine for AML Minimal Residual Disease
This trial tests a new type of immune therapy using your own T cells (white blood cells) that are trained to fight AML cancer cells. It's designed for patients whose AML has mostly gone away with chemotherapy but still has traces of cancer detectable in blood or bone marrow tests.
Seattle, WashingtonAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Gilbert, ArizonaAges 18 years+ - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT06915038Recruiting
Measuring tumor DNA in blood for HPV-positive throat cancer
This study looks at a blood test that finds DNA from HPV-related throat tumors. It may help doctors decide on surgery and check if the cancer is completely removed.
Carmel, IndianaAges 18 years+ - NCT02015013RecruitingPhase 2
Blood cell collection study for immune system disorders
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
Bethesda, MarylandAges 18–65 - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05544526RecruitingPhase 1
CAR T cell treatment for brainstem spinal cord tumor in children
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
LondonAges Up to 16 years
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,710 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.